Amyl nitrite inhalation
PreclinicalSmall molecule
Amyl nitrite inhalation is one of 15 small molecule programs targeting Hypertrophic Cardiomyopathy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Hypertrophic Cardiomyopathy
#DrugCompanyPhaseTrials
1Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Aldactone
PfizerApproved
Zebeta
TevaApproved
Lexiscan
AstellasApproved
Adenocard
AstellasApproved
Bayer Aspirin
BayerApproved
Calan
VVal Adams
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Xarelto
WWim Janssens
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amyl nitrite inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMayo Clinic